SLS

SELLAS LIFE SCIE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.770
-0.010
-0.36%
Closed 16:43 07/06 EDT
OPEN
2.800
PREV CLOSE
2.780
HIGH
2.880
LOW
2.710
VOLUME
130.26K
TURNOVER
--
52 WEEK HIGH
12.44
52 WEEK LOW
1.455
MARKET CAP
18.61M
P/E (TTM)
-0.2472
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SLS stock price target is 8.50 with a high estimate of 9.00 and a low estimate of 8.00.

EPS

SLS News

More
Targeting The National Cancer Institute's #1- Ranked Cancer Antigen: SELLAS' Most Advanced Immunotherapy in Pivotal Phase 3 Study in AML and in Phase 1/2 Studies in Combination With PD1
Newsfile · 06/23 13:12
Solaris Advances Conditional Listing Approval; Closes C$1.2M Placement with Lundin
CNW Group · 06/11 13:30
SELLAS to Host Virtual Annual Meeting of Stockholders
GlobeNewswire · 05/22 13:30
SELLAS Life Sciences (SLS) Presents At UBS Global Healthcare Conference - Slideshow
Seeking Alpha - Article · 05/19 19:58
SELLAS Establishes Independent Data Monitoring Committee of Leading Clinical and Biostatistics Experts for Pivotal Phase 3 REGAL Clinical Trial
GlobeNewswire · 05/18 13:30
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14)
Benzinga · 05/15 11:49
SELLAS Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
GlobeNewswire · 05/14 21:33
SELLAS to Present at UBS Virtual Global Healthcare Conference
GlobeNewswire · 05/07 13:00

Industry

Pharmaceuticals
+0.74%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Symbol
Price
%Change

About SLS

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
More

Webull offers kinds of Sellas Life Sciences Group Inc stock information, including NASDAQ:SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.